Labeled for this condition
Medicines for chronic kidney disease
8 medicines have an FDA label indicated for chronic kidney disease; 4 are listed from generic labelers and 0 have a presentation in shortage now (FDA files, October 8, 2026).
Which medicines are labeled for chronic kidney disease?
Each label names the condition in its indications; the record shows the label's words. A list of labeled medicines is not a treatment plan.
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Losartan | Cozaar, Arbli | 43 labelers | $0.0327 per tablet 50 mg tablet | Yes | No current entry | 77 |
| Irbesartan | Avapro | 23 labelers | $0.107 per tablet 150 mg tablet | Yes | No current entry | 10 |
| Dapagliflozin | Farxiga | 22 labelers | $0.184 per tablet 10 mg tablet | No | No current entry | 0 |
| Captopril | none listed | 13 labelers | $0.228 per tablet 12.5 mg tablet | Yes | No current entry | 5 |
| Semaglutide | Wegovy, Ozempic, Rybelsus | none listed | $331.99 per mL 0.25-0.5 mg/dose (2 mg/3 mL) pen | Yes | A presentation being discontinued | 4 |
| Empagliflozin | Jardiance | none listed | $11.19 per tablet 10 mg tablet | No | No current entry | 2 |
| Canagliflozin | Invokana | none listed | $19.13 per tablet 100 mg tablet | No | No current entry | 0 |
| Finerenone | Kerendia | none listed | $22.86 per tablet 10 mg tablet | No | No current entry | 0 |
Source: FDA drug labels (indications) via openFDA; NDC Directory; CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price